glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
![glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1_ra_infographic.png)
![glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-17-01470/article_deploy/html/images/pharmaceuticals-17-01470-g001-550.jpg)
![glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41569-023-00849-3/MediaObjects/41569_2023_849_Fig1_HTML.png)
![glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]](https://www.frontiersin.org/files/Articles/137519/fnins-09-00092-HTML/image_m/fnins-09-00092-g001.jpg)
![glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]](https://www.frontiersin.org/files/Articles/1483792/xml-images/fphar-15-1483792-g001.webp)
![glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs44355-026-00069-9/MediaObjects/44355_2026_69_Fig1_HTML.png)






















